In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma

[1]  M. Atkins,et al.  Systemic therapy for renal cell carcinoma. , 2005, Cancer chemotherapy and biological response modifiers.

[2]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[3]  R. Fisker,et al.  Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival , 2002, British Journal of Cancer.

[4]  K. Hellstrand.  Histamine in cancer immunotherapy: a preclinical background. , 2002, Seminars in oncology.

[5]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[6]  R. Henriksson,et al.  Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Z. Kırkalı,et al.  Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma , 2001, International journal of urology : official journal of the Japanese Urological Association.

[8]  N. Rioux-Leclercq,et al.  Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. , 2001, Human pathology.

[9]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[10]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  U. Mellqvist,et al.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine? , 2000, Medical oncology.

[12]  S. Rosenberg,et al.  Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Ve,et al.  Contemporary approach to the classification of renal epithelial tumors. , 2000 .

[14]  V. Reuter,et al.  Contemporary approach to the classification of renal epithelial tumors. , 2000, Seminars in oncology.

[15]  M. Kato,et al.  Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. , 2000, Anticancer research.

[16]  K. Franssila,et al.  MIB-1 Immunoreactivity Correlates with Blood Vessel Density and Survival in Disseminated Malignant Melanoma , 1999, Oncology.

[17]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Fayers,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial , 1999 .

[20]  Gareth Griffiths,et al.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. , 1999, Lancet.

[21]  S Pestka,et al.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. , 1998, Cancer research.

[22]  S. Bentzen,et al.  Proliferative activity (MIB‐1 index) is an independent prognostic parameter in patients with high‐grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas , 1998, Histopathology.

[23]  D. Grandér,et al.  How does interferon exert its cell growth inhibitory effect? , 1997, European journal of haematology.

[24]  L. Sobin,et al.  TNM staging of renal cell carcinoma , 1997, Cancer.

[25]  L. Sobin,et al.  Union Internationale Contre le Cancer (UICC) and the American Joint TNM Staging of Renal Cell Committee on Cancer (AJCC) Carcinoma , 1997 .

[26]  P. Lipponen,et al.  Prognostic value of Ki-67 expression in renal cell carcinomas. , 1997, European urology.

[27]  P. Kosmidis,et al.  The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon α2b , 1996, Cancer Immunology, Immunotherapy.

[28]  R. Fietkau,et al.  Prognostic value of ploidy and proliferation markers in renal cell carcinoma , 1996, Cancer.

[29]  R. Motzer,et al.  Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[31]  C. Baxevanis,et al.  The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Hellstrand,et al.  Role of histamine in natural killer cell-mediated resistance against tumor cells. , 1990, Journal of immunology.

[33]  N. Bander,et al.  Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. , 1990, Cancer research.

[34]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[35]  W. Lees,et al.  ULTRASOUND-GUIDED CORE BIOPSY , 1989, The Lancet.

[36]  H. J. G. GUNDERSEN,et al.  Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[37]  J. Quesada,et al.  Renal cell carcinoma: antitumor effects of leukocyte interferon. , 1983, Cancer research.